Modelling of tumour growth and cytotoxic effect of docetaxel in xenografts

Computer Methods and Programs in Biomedicine

Volumn 114, Issue 3, 2014, Pages e3-

  Evans, Neil D ^a   Dimelow, Richard J ^b   Yates, James W T ^c  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b Wright Dose Ltd   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Biomedical systems; Cytotoxic agents; Parameter estimation; Structural identifiability; Tumour growth models; Xenograft tumour models

Indexed keywords

CYTOTOXICITY; DRUG PRODUCTS; PARAMETER ESTIMATION; TUMORS;

BIOMEDICAL SYSTEMS; CYTOTOXIC AGENTS; MECHANISTIC MODELING; PATHOPHYSIOLOGICAL; SOURCES OF INFORMATIONS; SPATIAL CONSTRAINTS; STRUCTURAL IDENTIFIABILITY; TUMOUR GROWTH MODELS;

PHYSIOLOGICAL MODELS;

DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BODY WEIGHT; BOLUS INJECTION; CELL PROLIFERATION; COMPARTMENT MODEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; HYPOXIC CELL; IC 50; MOUSE; NONHUMAN; PLASMA VOLUME; SINGLE DRUG DOSE; TUMOR GROWTH; XENOGRAFT; ALGORITHM; ANIMAL; BIOLOGICAL MODEL; CANCER TRANSPLANTATION; COMPUTER PROGRAM; DRUG SCREENING; HUMAN; METABOLISM; NEOPLASMS; PROCEDURES; TIME;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS; SOFTWARE; TAXOIDS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899100378     PISSN: 01692607     EISSN: 18727565     Source Type: Journal    
DOI: 10.1016/j.cmpb.2013.06.014     Document Type: Article

References (20)

1. Simeoni M., Magni P., Cammia C., Nicolao G., Croci V., Pesenti E., Germani M., Poggesi I., Rocchetti M. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Research 2004, 64:1094-1101.
2. Ribba B., Watkin E., Tod M., Girard P., Grenier E., You B., Giraudo E., Freyer G. A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. European Journal of Cancer 2011, 47:479-490.
3. Alarcón T., Byrne H., Maini P. A cellular automaton model for tumour growth in inhomogeneous environment. Journal of Theoretical Biology 2003, 225:257-274.
4. Bissery M. Preclinical pharmacology of docetaxel. European Journal of Cancer 1995, 31A(Suppl. 4):S1-S6.
5. Bradshaw-Pierce E., Eckhardt S., Gustafson D. a physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clinical Cancer Research 2007, 13(9):2768-2776. 10.1158/1078-0432.CCR-06-2362.
6. Bellman R., Åström K. On structural identifiability. Mathematical Biosciences 1970, 7:329-339.
7. Godfrey K., DiStefano J. Identifiability of model parameters. Identifiability of Parametric Models 1987, 1-20. Pergamon Press, Oxford, (Chap. 1). E. Walter (Ed.).
8. Pohjanpalo H. System identifiability based on the power series expansion of the solution. Mathematical Biosciences 1978, 41:21-33.
9. Ljung L., Glad T. On global identifiability for arbitrary model parametrizations. Automatica 1994, 30:265-276.
10. Saccomani M., Audoly S., D'Angiò L. Parameter identifiability of nonlinear systems: the role of initial conditions. Automatica 2003, 39:619-632.
11. Bearup D., Evans N., Chappell M. The input-output relationship approach to structural identifiability analysis. Computer Methods and Programs in Biomedicine 2013, 109:171-181.
12. Evans N., Moyse H., Lowe D., Briggs D., Higgins R., Mitchell D., Zehnder D., Chappell M. Structural identifiability of surface binding reactions involving heterogeneous analyte: application to surface plasmon resonance experiments, provisionally. Automatica 2013, 49:48-57.
13. Sparreboom A., Tellingen O., Nooijen W., Beijnen J. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anti-Cancer Drugs 1998, 9:1-17.
14. McLeod H., Kearns C., Kuhn J., Bruno R. Evaluation of the linearity of docetaxel pharmacokinetics. Cancer Chemotherapy and Pharmacology 1998, 42:155-159.
15. Jumbe N., Xin Y., Leipold D., Crocker L., Dugger D., Mai E., Sliwkowski M., Fielder P., Tibbitts J. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice. Journal of Pharmacokinetics and Pharmacodynamics 2010, 37:221-242.
16. Friberg L., Henningsson A., Maas H., Nguyen L., Karlsson M. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. Journal of Clinical Oncology 2002, 20:4713-4721.
17. Denis-Vidal L., Joly-Blanchard G., Noiret C. Some effective approaches to check identifiability of uncontrolled nonlinear rational systems. Mathematics and Computers in Simulation 2001, 57:35-44.
18. Forsman K. Constructive Commutative Algebra in Nonlinear Control Theory 1991, Linköping Institute of Technology, number 261, (Ph.D. Thesis).
19. AEA Technology Facsimile (Version 4.0) Technical Reference 1995, Harwell Laboratory, Didcot, Oxfordshire, UK.
20. Riches A., Sharp J., Brynmor Thomas D., Vaughan Smith S. Blood volume determination in the mouse. Journal of Physiology 1973, 228:279-284.